Clinical Dilemmas in Viral Liver Disease / Edition 1

Paperback (Print)
Buy New
Buy New from
Used and New from Other Sellers
Used and New from Other Sellers
from $80.03
Usually ships in 1-2 business days
(Save 24%)
Other sellers (Paperback)
  • All (8) from $80.03   
  • New (6) from $80.03   
  • Used (2) from $101.70   


Clinical Dilemmas in Viral Liver Disease is a practical up-to-date handbook providing answers to the questions and challenges that arise in day-to-day practice. Each short chapter addresses a different topic and provides evidence-based guidance on subjects ranging from optimizing current management through to special management problems and novel treatments. This book is suitable for all medical professionals involved in the care of patients with viral liver disease: established and trainee hepatologists, pediatric hepatologists, pathologists, radiologists, transplant surgeons and nurse specialists

Read More Show Less

Product Details

  • ISBN-13: 9781405179058
  • Publisher: Wiley
  • Publication date: 5/10/2010
  • Series: Clinical Dilemmas (UK) Series
  • Edition number: 1
  • Pages: 272
  • Product dimensions: 7.40 (w) x 9.60 (h) x 0.70 (d)

Meet the Author

Graham R Foster PhD FRCP

Professor of Hepatology, Queen Marys University of London, Blizard Institute of Cell & Molecular Science, The Royal London Hospital, London, UK

K. Rajender Reddy MD, FACP, FACG, FRCP

Professor of Medicine, Professor of  Medicine  in Surgery, Director of Hepatology, Medical Director of Liver Transplantation, University of Pennsylvania, PA, USA

Read More Show Less

Table of Contents

Investigating the liver

Non-invasive markers of fibrosis - useful or useless?

Liver biopsy in HCV with easy to treat disease - should we bother?

The inactive carrier - what tests should we do for HBeAg negative patients with minimal HBV DNA and near normal LFTs?

Screening for HCC in patients with viral cirrhosis - is ultrasound enough?

HBV pre-treatment sequencing. Prudent precaution or unnecessary luxury?

Genomic investigations in viral hepatitis - likely to help or hinder?

Today's therapies

i) HCV
How should HCV Genotype 1 Non-responders be managed?

How should HCV Genotype 1 patients who relapse or breakthrough be managed?

How should HCV Genotype 2/3 Non-responders be managed?

How should HCV Genotype 2/3 patients who relapse or breakthrough be managed?

How should we treat acute HCV infection?

How should we treat HCV in patients with red cell dyscrasias?

How should we treat HCV in dialysis patients?

How should we treat HCV in patients with a renal transplant?

How should we treat HCV in psychotic patients?

What management strategies can we use for morbid obesity and HCV?

What management strategies are appropriate for Cytopenias and hepatitis C? 

How should patients with multiple HCV genotypes be managed?

How should we treat HCV in injecting drug users?

How should we treat HIC and HCV/HBV?

How should we treat HCV, anti LKM antibodies and autoimmune disorders?

How should we manage an easy to treat virus in difficult patients? -HCV in obese cirrhotics with genotype 3

How should we treat HCV in children?

Controlling symptoms in chronic HCV ON AND OFF TREATMENT - does anything work?

Complementary therapies in chronic HCV - exploitation or something to offer?

HCV in the post liver transplant patient: what options do we have?

How should we manage viral hepatitis in bone marrow transplant patients?

ii) HBV
What's the best way to manage acute HBV?

How should we manage HBeAg positive patients with near normal LFTs?

How should we manage HBeAg negative patients with minimal changes on liver biopsy?

HBV combination therapy ab initio or add in regimes?

How should we manage HBV infection in children?

HBV and the second pregnancy - what should we do when the first child has failed to respond to vaccination?

How should HBV in surgeons be managed?

What can we do about HBV and the poorly compliant patient?

How can we manage acute liver failure and HBV?

High risk needlestick injuries in vaccine failures?

How best to manage HBV in the immunocompromised patient?

What can we do in Lamivudine and Adefovir resistance?

How do we manage HBV following unsuccessful interferon therapy?

How do we manage co-infection with HBV and HCV?

iii) HDV


Clinical set up

What is the role of the nurse specialist?

Non specialist management of viral liver disease - cost effective or foolish cost cutting?

The future

Clinical trial design in chronic HCV - with or without PegIFN and ribavirin?

Protease and polymerase inhibitors for HCV

HCV vaccines - coming soon?

HBV - new nucleotides and nucleosides - can we expect any more?

HBV novel drugs: what's in the pipeline?

HBV - therapeutic vaccines - hope or hype?

Novel interferons - is there life in the old dog yet?

On-going controversies

i) HBV therapy
Is Interferon a valuable first line therapy for HBeAg positive HBV?

Should nucleosides always be used first in HBeAg positive HBV?

ii) HCV

Will most patients with HCV die from their disease?

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star


4 Star


3 Star


2 Star


1 Star


Your Rating:

Your Name: Create a Pen Name or

Barnes & Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation


  • - By submitting a review, you grant to Barnes & and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Terms of Use.
  • - Barnes & reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)